|
EP2794565B1
(en)
|
2011-12-21 |
2017-07-26 |
Novira Therapeutics Inc. |
Hepatitis b antiviral agents
|
|
CA2881057C
(en)
|
2012-08-28 |
2020-10-27 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
HK1215030A1
(zh)
*
|
2012-11-09 |
2016-08-12 |
Indiana University Research And Technology Corporation |
用於hbv組裝效應劑的替代用途
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
JP6466348B2
(ja)
|
2013-02-28 |
2019-02-06 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
HUE033542T2
(en)
|
2013-04-03 |
2017-12-28 |
Janssen Sciences Ireland Uc |
Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
|
|
TW202126620A
(zh)
|
2013-05-17 |
2021-07-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
KR20250012194A
(ko)
|
2013-06-17 |
2025-01-23 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
JP6738728B2
(ja)
|
2013-06-17 |
2020-08-19 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ−Ｃａｓ系、ベクターおよび組成物の送達および使用
|
|
ES2777217T3
(es)
|
2013-06-17 |
2020-08-04 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
|
|
WO2015011281A1
(en)
|
2013-07-25 |
2015-01-29 |
Janssen R&D Ireland |
Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
MX368158B
(es)
|
2013-10-23 |
2019-09-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
KR20160097338A
(ko)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
CN105899658B
(zh)
|
2013-12-12 |
2020-02-18 |
布罗德研究所有限公司 |
针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
CN111206032B
(zh)
|
2013-12-12 |
2024-07-19 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
US9181288B2
(en)
|
2014-01-16 |
2015-11-10 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
JP6553059B2
(ja)
|
2014-02-05 |
2019-07-31 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｈｂｖ感染の治療のための併用療法
|
|
PL3102572T3
(pl)
|
2014-02-06 |
2019-04-30 |
Janssen Sciences Ireland Uc |
Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
|
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
|
RU2711750C2
(ru)
*
|
2014-06-20 |
2020-01-21 |
Дрексель Юнивёрсити |
Меченый антиген е гепаднавируса и его применение в скрининге противовирусных веществ
|
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016106244A1
(en)
|
2014-12-24 |
2016-06-30 |
The Broad Institute Inc. |
Crispr having or associated with destabilization domains
|
|
EP3271019A1
(en)
|
2015-03-19 |
2018-01-24 |
Novira Therapeutics Inc. |
Azocane and azonane derivatives and methods of treating hepatitis b infections
|
|
WO2016161268A1
(en)
|
2015-04-01 |
2016-10-06 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antviral agents
|
|
US10738035B2
(en)
|
2015-05-13 |
2020-08-11 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
EP3929287A3
(en)
|
2015-06-18 |
2022-04-13 |
The Broad Institute, Inc. |
Crispr enzyme mutations reducing off-target effects
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
WO2017011552A1
(en)
|
2015-07-13 |
2017-01-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2017015451A1
(en)
*
|
2015-07-22 |
2017-01-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
US10301255B2
(en)
|
2015-07-22 |
2019-05-28 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
KR101771309B1
(ko)
*
|
2015-07-24 |
2017-08-24 |
재단법인 목암생명과학연구소 |
B형 간염 바이러스의 ｃｃｃＤＮＡ 형성 억제용 약학 조성물
|
|
AR106192A1
(es)
|
2015-09-29 |
2017-12-20 |
Novira Therapeutics Inc |
Formas cristalinas de un agente antiviral contra la hepatitis b
|
|
WO2017136403A1
(en)
|
2016-02-02 |
2017-08-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
KR102398439B1
(ko)
|
2016-03-07 |
2022-05-16 |
이난타 파마슈티칼스, 인코포레이티드 |
B형 간염 항바이러스제
|
|
WO2017181141A2
(en)
|
2016-04-15 |
2017-10-19 |
Novira Therapeutics, Inc. |
Combinations and methods comprising a capsid assembly inhibitor
|
|
EP3468561A4
(en)
|
2016-06-10 |
2019-12-04 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
EP4650005A3
(en)
|
2016-07-15 |
2026-01-28 |
Viracta Subsidiary, Inc. |
Histone deacetylase inhibitors for use in immunotherapy
|
|
JP6811338B2
(ja)
*
|
2016-12-13 |
2021-01-13 |
エーエム サイエンシーズ インコーポレイテッド |
Ｂ型肝炎の予防または治療用医薬組成物
|
|
SG11202001685TA
(en)
|
2017-08-28 |
2020-03-30 |
Enanta Pharm Inc |
Hepatitis b antiviral agents
|
|
WO2019110589A1
(en)
*
|
2017-12-04 |
2019-06-13 |
F. Hoffmann-La Roche Ag |
Pyrrolo[2,3-b]pyrazine compounds as cccdna inhibitors for the treatment of hepatitis b virus (hbv) infection
|
|
US10723733B2
(en)
|
2017-12-06 |
2020-07-28 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2019113173A1
(en)
|
2017-12-06 |
2019-06-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
US11058678B2
(en)
|
2018-01-22 |
2021-07-13 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
SG11202007097QA
(en)
|
2018-03-14 |
2020-08-28 |
Janssen Sciences Ireland Unlimited Co |
Capsid assembly modulator dosing regimen
|
|
US10729688B2
(en)
|
2018-03-29 |
2020-08-04 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2019240503A1
(ko)
*
|
2018-06-12 |
2019-12-19 |
주식회사 에이엠사이언스 |
B형 간염 예방 또는 치료용 조성물
|
|
WO2019240504A1
(en)
*
|
2018-06-12 |
2019-12-19 |
Am Sciences Co., Ltd. |
Modified oligonucleotides for inhibition of target gene expression
|
|
TW202024093A
(zh)
|
2018-09-21 |
2020-07-01 |
美商安塔製藥公司 |
作為抗病毒劑之官能化雜環
|
|
CN112888480A
(zh)
*
|
2018-10-24 |
2021-06-01 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒疾病的新型三环化合物
|
|
EP3883570A4
(en)
|
2018-11-21 |
2022-07-13 |
Enanta Pharmaceuticals, Inc. |
FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
|
|
AU2020223865A1
(en)
|
2019-02-22 |
2021-07-15 |
Janssen Sciences Ireland Unlimited Company |
Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
|
|
BR112021021454A2
(pt)
|
2019-05-06 |
2021-12-21 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
|
|
TWI853940B
(zh)
|
2019-05-31 |
2024-09-01 |
美商維拉克塔股份有限公司 |
以組蛋白去乙醯酶抑制劑治療病毒相關癌症之方法
|
|
WO2020247444A1
(en)
|
2019-06-03 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
|
WO2020247561A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
|
US11472808B2
(en)
|
2019-06-04 |
2022-10-18 |
Enanta Pharmaceuticals, Inc. |
Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
|
|
WO2021007488A1
(en)
|
2019-07-11 |
2021-01-14 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
WO2021055425A2
(en)
|
2019-09-17 |
2021-03-25 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
JP2022550454A
(ja)
*
|
2019-10-02 |
2022-12-01 |
ユニバーシティ オブ ワシントン |
Ｂ型肝炎ウイルス感染の治療のための組成物及び方法
|
|
US11802125B2
(en)
|
2020-03-16 |
2023-10-31 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
|
JP2023538630A
(ja)
*
|
2020-08-21 |
2023-09-08 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
|
|
CN112274516B
(zh)
*
|
2020-10-26 |
2022-08-05 |
中山大学附属第三医院 |
一种新型含碘抗病毒药物
|
|
IT202100005054A1
(it)
*
|
2021-03-04 |
2022-09-04 |
Azienda Ospedaliero Univ Di Parma |
Composto farmaceutico per l’uso in un trattamento terapeutico dell’infezione cronica da hbv e metodo per l’identificazione di linfociti esauriti
|